Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy
View abstract on PubMed
Summary
This summary is machine-generated.Lysosome-targeting chimeras (LYTACs) selectively degrade programmed death-ligand 1 (PD-L1) in liver cancer cells. Host cell PD-L1, not tumor cell PD-L1, is crucial for anti-PD-1 therapy response in mice.
Area Of Science
- Immunology
- Oncology
- Biotechnology
Background
- Programmed death-ligand 1 (PD-L1) staining guides anti-PD-1 therapy, but its expression varies across tumor and host cells.
- The differential impact of PD-L1 on tumor cells versus host cells on anti-PD-1 therapy response remains unclear.
Purpose Of The Study
- To develop a novel LYTAC platform for selective PD-L1 degradation in specific cell subsets.
- To investigate the role of tumor cell- versus host cell-expressed PD-L1 in anti-PD-1 therapy response.
Main Methods
- Synthesized polymer-based LYTACs targeting PD-L1 and liver cells via asialoglycoprotein receptor (ASGPR).
- Utilized positron emission tomography (PET) imaging with 89Zr-αPD-L1/Fab to assess PD-L1 expression.
- Evaluated LYTAC efficacy in a mouse model of liver cancer.
Main Results
- LYTACs successfully degraded PD-L1 on liver cancer cells via lysosomal pathways without affecting host cells.
- PET imaging revealed host cell PD-L1, not tumor cell PD-L1, is critical for anti-PD-1 therapy efficacy in a mouse liver cancer model.
Conclusions
- The LYTAC strategy combined with PET imaging offers a powerful tool to dissect the in vivo roles of specific protein subsets.
- This approach can overcome limitations of traditional knockout models for studying protein function in complex biological systems.

